Adverum biotechnologies inc ADVM.US 總覽分析
ADVM 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼
ADVM 近期報酬表現
-3.56%
Adverum biotechnologies inc
4.57%
同產業平均
3.26%
S&P500
與 ADVM 同產業的標的表現
- KYTX Kyverna therapeutics inc價值 -趨勢 2 分波段 4 分籌碼 1 分股利 1 分查看更多
ADVM 公司資訊
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. It discovers and develops gene therapy product candidates that provide durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration (wet AMD). Its other partnered programs include BGTF-027 (AAV.7m8-L-opsin), a gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (BCM) via a single IVT injection.